8-K 1 v062948_8k.htm Unassociated Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): January 12, 2007


Calypte Biomedical Corporation
(Exact name of Company as specified in its charter)


Delaware
000-20985
06-1226727
(State or Other Jurisdiction)   
(Commission File Number)
(I.R.S. Employer Identification)
of Incorporation)
   

5 Centerpointe Drive, Suite 400, Lake Oswego, OR 97035
(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (971) 204-0282


N/A
 (Former name or former address, if changed since last report)

o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 40.13e-4(c))
 


Item 5.02  Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

(b) On January 12, 2007, Theodore R. Gwin ceased his employment as Chief Financial Officer of Calypte Biomedical Corporation to pursue other interests. Roger I. Gale, Chief Executive Officer, will assume the role of Chief Financial Officer on an interim basis until a successor to Mr. Gwin is named.

 

SIGNATURES

Pursuant to the requirement of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: Lake Oswego, Oregon
  January 19, 2007
     
  Calypte Biomedical Corporation
 
 
 
 
 
 
  By:   /s/ Roger I. Gale
 
Roger I Gale
  Chief Executive Officer